Lipids in non-insulin dependent diabetes: a case for treatment?
作者信息
Mikhailidis D P, Barradas M A
出版信息
J R Soc Med. 1991 Nov;84(11):694.
Abstract
摘要
相似文献
1
Lipids in non-insulin dependent diabetes: a case for treatment?非胰岛素依赖型糖尿病中的脂质：是否需要治疗？
J R Soc Med. 1991 Nov;84(11):694.
2
3
Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.2型糖尿病治疗与大血管并发症——脂肪和糖形成了危险的“蛋奶酥”。
Metab Syndr Relat Disord. 2009 Apr;7(2):79-81. doi: 10.1089/met.2008.0092.
4
Diabetic macrovascular disease and serum lipids: is there a connection?
Diabet Med. 1992 Jan-Feb;9(1):9-14. doi: 10.1111/j.1464-5491.1992.tb01707.x.
5
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy.2型糖尿病中基质金属蛋白酶-9及金属蛋白酶组织抑制剂-1和-2：1年心血管风险降低治疗的效果
Diabetes Care. 2004 Aug;27(8):2049-51. doi: 10.2337/diacare.27.8.2049.
6
Vascular disease and lipids in diabetes.
Med Clin North Am. 1998 Jul;82(4):931-48. doi: 10.1016/s0025-7125(05)70030-4.
7
Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities.
Diabetes Care. 1999 Apr;22 Suppl 3:C6-9.
8
Symposium on treatment of diabetic complications. 5. Strict glycemic control and diabetic microvascular complications.糖尿病并发症治疗研讨会。5. 严格血糖控制与糖尿病微血管并发症
Intern Med. 1997 Feb;36(2):144-7. doi: 10.2169/internalmedicine.36.144.
9
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus.糖尿病患者血脂治疗立场文件。
Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S97-S101. doi: 10.1055/a-1018-9228. Epub 2019 Dec 20.
10
Determination of the glycemic threshold for the regression or prevention of diabetic microangiopathies, and the insulin injection regimen to establish strict glycemic control in NIDDM.确定糖尿病微血管病变消退或预防的血糖阈值，以及在非胰岛素依赖型糖尿病中建立严格血糖控制的胰岛素注射方案。
Jpn J Med. 1991 Nov-Dec;30(6):618-21. doi: 10.2169/internalmedicine1962.30.618.
本文引用的文献
1
Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus.
Diabetes Care. 1984 Mar-Apr;7(2):174-9. doi: 10.2337/diacare.7.2.174.
2
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.止血功能与缺血性心脏病：诺斯威克公园心脏研究的主要结果
Lancet. 1986 Sep 6;2(8506):533-7. doi: 10.1016/s0140-6736(86)90111-x.
3
Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus.糖尿病中的血小板功能、血小板类前列腺素和血管前列环素
Prostaglandins Leukot Essent Fatty Acids. 1989 Mar;35(4):197-212. doi: 10.1016/0952-3278(89)90003-3.
4
Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.苯扎贝特对高脂血症1型糖尿病患者血脂、脂蛋白和纤维蛋白原影响的双盲安慰剂对照研究
Diabet Med. 1990 Sep-Oct;7(8):736-43. doi: 10.1111/j.1464-5491.1990.tb01479.x.
5
6
Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions.
Curr Med Res Opin. 1990;12(4):207-14. doi: 10.1185/03007999009111649.
7
Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
J Cardiovasc Pharmacol. 1990;16 Suppl 9:S21-4; discussion S24-5.
Zotero 插件